We have previously synthesized a new cationic liposome that displays high efficiency and low toxicity, 3␤ [l-ornithinamide-carbamoyl] 
Introduction
For intraperitoneal disseminated tumors, such as ovarian cancer or pancreatic cancer, intensive therapies using surgical techniques, radiation, and chemotherapy are still ineffective. 1, 2 Recently, based on the fact that many human cancers are the result of accumulated genetic lesions that culminate in a transformed malignant phenotype, 3 investigation into the potential usefulness of gene therapy for peritoneal metastases has been initiated. 4 Numerous reports have described cancer gene therapy with intraperitoneal administration of viral gene carriers, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] while there are only a few reports of intraperitoneal administration of DNA-cationic liposome complexes for gene transfer into intraperitoneal disseminated tumors.
Among the various gene carriers, viral vectors are the most widely used because of their efficiency. However, several recurring issues about their safety have led to a reconsideration of the use of viral vectors in human clinical trials. 22 Over the past decades there have been many attempts to design a nonviral vector that can achieve the level of gene expression attained by viral vectors, including naked DNA injection, gene gun, electroporation, lipoplex and polyplex. 23, 24 In response to this challenge, we have previously synthesized a novel cationic liposome, 3␤[l-ornithinamide-carbamoyl] cholesterol (O-Chol, Figure 1) using solid-phase synthesis, and demonstrated its relatively high efficiency and low toxicity in vitro. 25 In this study, we studied the potential for gene delivery by O-Chol in treating cancer. For this purpose, we first established a novel peritoneal disseminated cancer model in the nude mouse, with which it is possible to quantitatively assess cancer mass. We evaluated the efficiency and toxicity of O-Chol in vitro and the efficiency and specificity in vivo for peritoneal disseminated tumor on the basis of our model. O-Chol showed high levels of gene expression in vitro and in vivo with tumor specificity. Our results suggest that the O-Chol:DNA lipoplex is a promising tool in gene therapy for patients with peritoneal disseminated cancer. 26 and that amide form of ornithine contains a positively charged terminal amine group.
Results

In vitro cytotoxicity and transfection efficiency of transfection reagents in different cell lines
The cytotoxicity of the O-Chol liposome in different human ovarian cancer cell lines (OV-CA-2774, OV-CAR-3 and SK-OV-3) was compared with that of DC-Chol liposome, lipofectin, lipofectAMINE, and FuGENE 6, all of which are widely used as gene transfer reagents. As shown in Figure 2 , DC-Chol showed dramatic loss of cell viability as the amount of DC-Chol increased in all three cell lines. Cytotoxicity of O-Chol was similar to the other reagents in the OV-CA-2774 cell line (Figure 2a) . At the concentration for optimal in vitro transfection of O-Chol (about 5 g/ml), about 100% of the cell survived for 48 h in all cell lines. However, at the concentrations over 40 g/ml in OV-CAR-3 and SK-OV-3 cell lines, more cytotoxicity of O-Chol than lipofectin, lipofectAMINE and FuGENE 6 was observed. The cytotoxicity profile of liposome:DNA complexes was generally lower than that of liposome alone, but those patterns had high similarity (data not shown).
To determine its efficiency, O-Chol was compared directly with the other above-mentioned commercial transfection reagents. As shown in Figure 3 , the O-Chol liposome was the most effective carrier in transfections of all the human ovarian cancer cell lines tested. In the OV-CA-2774 cell line, 13.1-fold, 14.1-fold, 2.1-fold, and 4.5-fold enhancement of luciferase activity was observed compared with lipofectin, lipofectAMINE, FuGENE 6, and DC-Chol, respectively, in serum-free conditions (P Ͻ 0.001 in all cases). Although the transfection efficiency of each transfection reagent varied slightly according to the cell type, the relative efficiencies in each cell line were in the order: O-Chol > FuGENE 6 > DC-Chol > lipofectAM-INE > lipofectin. It is noteworthy that the transfection efficiency of O-Chol was higher in medium containing 10% serum than in serum-free medium for OV-CAR-3 (by 169%, P Ͻ 0.05) and SK-OV-3 (by 142%, P Ͻ 0.05) cell lines, and nearly equivalent in the OV-CA-2774 cell line (103%). We chose the OV-CA-2774 cell line for our in vivo tumor model because these cells produce disseminated intraperitoneal cancer and malignant ascites when seeded intraperitoneally.
Assessment of tumor development in the peritoneal cavities of nude mice
To test the in vivo efficiency of gene transfer, we established a disseminated intraperitoneal cancer model in expressed using an enzyme-linked immunosorbent assay (ELISA), it was possible to accurately measure the tumor burden of each organ at each time point. From the distribution shown in Figure 4a , cancers developed predominantly on the peritoneum, pancreas, mesentery and ovary, and tumors grew over time. Other organs showed lower levels of cancer for these 5 weeks and did not show an increasing pattern of tumor growth. Because the amount of CAT expressed in intraperitoneal organs was extremely high compared with the CAT expressed by injected cancer cells, it was evident that the observed levels of CAT were not due simply to contamination by the Gene Therapy inoculated CAT-expressing cells. The number of ascites and the weights of the nude mice were also evaluated for 5 weeks after inoculation (Figure 4b ). The weight differences between control and cancer-inoculated mice were not significant. However, the cancer-inoculated mice became cachexic with time. The loss of muscle mass was compensated by the increase in ascites, which was first noticed after about 1 week. Ascites increased up to 5 ml at 5 weeks, and changed from serous to serosanguinous fluid during weeks 2-4. These data may provide a useful parameter for the quantitative evaluation of potential therapeutic effects of genes with anti-tumor and antiascites effects. Figure 4c and d show abundant tumor nodules on the surface of the mesentery at 2 weeks after inoculation, and their microscopic appearance after haematoxylin-eosin staining. Histologically, cryosections of the mesenteric nodules showed glandular or trabecular arrangement of malignant epithelial cells (ovarian cancer cells) and desmoplastic reaction. The histological findings resembled those of human ovarian cancer.
In vivo efficiency and tumor-cell selectivity after intraperitoneal gene delivery
Next, the transfection efficiency of O-Chol and other transfection agents was compared in vivo in our model of peritoneal disseminated cancer. We analyzed the level of reporter gene expression in two ways. First, luciferase activity was expressed per milligram of tissue protein ( Figure 5a ). Second, to correct for the different tumor burden of each organ, we expressed luciferase activity per amount of CAT (Figure 5b ), ie CAT gene expression was used as an internal control to overcome the differences in tumor burden.
In Figure 5a , similar results to those of in vitro transfection experiments were observed. O-Chol was more efficient than any other transfection agents. DC-Chol showed less luciferase activity, but lipofectAMINE and FuGENE 6 showed insignificant luciferase activity. Remarkably, when the FuGENE 6:DNA complex was injected intraperitoneally, mice developed labored breathing and irritable behavior, indicating that the FuG-ENE 6:DNA complex is not tolerated by mice in vivo. As expected, high levels of luciferase activity were detected in O-Chol and DC-Chol transfectants, mainly in the ascitic cells, pancreas, mesentery, and ovaries in which cancer cells predominantly grew. However, the levels of luciferase in the harvested organs are, at best, only 10% of the levels achieved in vitro. O-Chol showed a two-to three-fold increase in luciferase activity (RLU/mg protein) compared with DC-Chol in the pancreas, mesentery and ovary. As shown in Figure 5b , when the different tumor burden of each organ was corrected per amount of CAT, the O-Chol liposome was still the most effective carrier in most peritoneal organs, especially the pancreas, mesentery and ovary, in which there was 4.8-fold, 4.1-fold, and 5.2-fold enhancement of luciferase activity (RLU/pg CAT), respectively, compared with DCChol. Interestingly, the relationship between the mass of the tumor burden (pg CAT) and the transfection efficiency (RLU/mg protein) could be correlated linearly (Figure 5c ), which has the following implications. First, O-Chol showed significant selectivity for cancer cells, rather than normal cells of the abdominal organs. Second, the O-Chol:DNA complex showed similar transfection efficiency in the tumor cells of different organs. As seen Gene Therapy in Figure 5c , when the regression curves for each transfection reagent and Tukey multiple comparison test using a generalized linear model were used, O-Chol showed significantly higher transfection efficiency than other commercial transfection reagents in vivo (P Ͻ 0.05).
␤-Galactosidase gene expression study
The ␤-galactosidase gene with a nuclear localization signal was used to prevent possible background staining. Histochemical analyzis of sections from the abdominal organs injected with the plasmid ACP-nlsLacZ DNA demonstrated ␤-galactosidase activity only in cancer cells, predominantly in the pancreas and ovary where cancer development was most evident (Figure 6 ). In control animal, where media without O-Chol:DNA complex was injected into cancer-inoculated mice, there was no blue staining. It was difficult to accurately quantitate the percentage of cells expressing ␤-galactosidase activity in tumors because these cells were often noncontiguous and quite focal. However, it was clear that the uptake of DNA and/or its expression is a relatively low-frequency event and involves only a small fraction of tumor cells, ie less than 1% of cells expressed nlsLacZ.
Discussion
Because cytotoxicity is one of the major hurdles in the application of many transfection agents, an important feature of our cationic liposome is its low toxicity for cells at the concentrations required for optimal transfection. Even though O-Chol had the same or slightly greater toxicity than other commercial transfection agents at the high concentrations over 40 g/ml, about 100% of the cell survived for 48 h in all cell lines at the concentration for optimal in vitro transfection of O-Chol (about 5 g/ml). The effects of the liposomes on cell viability vary with different cell lines, and we have previously reported that O-Chol also displays lower toxicity for 293, NIH3T3, and HepG2 cell lines. 25 With the in vitro transfection assay, O-Chol displayed the highest transfection efficiency for all human ovarian cancer cell lines tested, with FuGENE 6, DC-Chol, lipofectin, lipofectAMINE following in that order. The transfection efficiency of O-Chol was markedly higher in the serum-containing medium than in the serum-free medium for the OV-CAR-3 and SK-OV-3 cell lines. The efficiency of normal cationic liposome-mediated gene expression often decreases with the addition of serum. It is thought that the positive charges on the lipoplex are neutralized by negatively charged components of serum, resulting in an immediate aggregation of vectors and hence a blocking of lipoplex uptake by cells. 27 We propose that the ability of O-Chol to overcome the inhibitory effects of serum arises from its cholesterol backbone, which inhibits its association with serum proteins and decreases liposome leakage. 27, 28 Furthermore, the greater hydrophilicity of O-Chol compared with other reagents, especially DC-Chol, may increase the liposomal half-life and cellular uptake. [29] [30] [31] Interestingly, O-Chol and FuG-ENE 6 seemed to work better in serum-containing medium. Because transfection efficiency depends on cell proliferation, we speculate that the transduced gene is more readily expressed in rapidly proliferating cells in Gene Therapy serum-containing medium when liposomes are serumtolerant. Moreover, the higher efficiency in the presence of serum could be due to the structural characteristics of O-Chol/DOPE itself. Previously, the formulations of DC-6-14/DOPE/Chol demonstrated transfection activity in medium with 10% serum that exceeded the activity observed under serum-free conditions. 19 The high transfection efficiency of O-Chol in the presence of serum suggests it could be used efficiently for in vivo transfection. Indeed, in the in vivo tumor model, our data showed that O-Chol was the most effective carrier for gene delivery.
To date, the general evaluation of tumors in cancer models involved autopsy with pathological confirmation. There has been no work as yet in the quantitative assessment of tumor progression. Using our novel cancer model, an exact assessment of the tumor burden was possible by evaluating the CAT level for each organ because we had inoculated CAT-transduced cancer cells into the mice. Therefore, application of our cancer model allows a more valid comparison of transfection efficiency among different lipoplexes in comparative studies, because it reduces the errors arising from irregular cancer development. Furthermore, it could also make possible a quantitative evaluation of potential therapeutic effects.
In our peritoneal disseminated tumor model, the OChol:DNA complex was transferred to tumor cells in a selective manner, as shown in Figures 5 and 6 . This phenomenon could be partly attributable to the fact that other abdominal organs are surrounded by fibrous capsules that act as barriers to the entry of liposome complex as well as tumor cells. 32 However, our data, which show that ␤-galactosidase expression was limited to tumor cells only, and not to normal cells in the pancreas, which does not have a fibrous capsule, indicate that the transgene was preferentially expressed in the tumors. In principle, cellular uptake of a lipoplex is a nonspecific process. The positively charged complex binds to the negatively charged cell membrane electrostatically. However, proliferating cell lines such as cancer cells can be transfected much more efficiently than normal cells, 33 while nondividing or post-mitotic cells are particularly resistant to transfection. It has been proposed that plasmids can enter the nucleus more easily when the nuclear membrane of dividing cells disappears during the M phase of the cell cycle. This O-Chol-mediated selectivity may be useful for cancer-specific gene therapy.
In the gene expression study, even though the levels of luciferase gene expression at injected sites were meaningful, the transfection efficiency using ␤-galactosidase plasmid DNA was very low because of its weak sensitivity. 34 Only a small number of scattered blue cells were observed. Although the transfection efficiency mediated by intraperitoneal gene delivery is relatively low, genes encoding a secreted protein with therapeutic potential may overcome this handicap using a paracrine effect, secreting adequate protein to reach physiologically meaningful levels locally. 35, 36 In summary, using an in vitro and in vivo quantitative intraperitoneal disseminated cancer model, we have shown that the O-Chol liposome offers potential advantages over other commercial transfection reagents because of its significantly enhanced efficiency, lesser dependence on serum and high selectivity for tumor cells. These results suggest that the O-Chol:DNA lipoplex is a promising tool in gene therapy for patients with ovarian cancers disseminated in the peritoneal cavity.
Materials and methods
Plasmid DNA preparation
The firefly luciferase gene and ␤-galactosidase gene were used as reporter genes to monitor the results of gene transfer. The luciferase expression plasmid (pCNluciferase) and ␤-galactosidase expression plasmid (ACPnlsLacZ) were constructed by subcloning cDNA of Photinus pyralis luciferase or E. coli ␤-galactosidase together with a 21 amino acid nuclear localization signal from SV40 large T antigen into pCN and ACP, respectively. The pCN vector contains the HCMV IE promoter and its entire 5' untranslated region consisting of 122-bp exon 1, 827-bp intron 1, and 16-bp exon 2. Levels of expression from pCN are higher than from vector with only the CMV promoter. 36 The ACP vector contains the HCMV IE promoter flanked by inverted terminal repeats from adeno-associated virus 2. 37 In the OV-CA-2774 cell line, the transfection efficiency of ACP was about half that of pCN (data now shown).
Plasmid DNA was transformed into E. coli TOP10 competent cells, and highly purified covalently closed circular plasmid DNA was isolated using a Qiagen Plasmid Mega Kit (Valencia, CA, USA) according to the manufacturer's instructions. Plasmids were precipitated in isopropanol, washed twice with 70% ethanol, and resuspended in distilled water. DNA was stored at -20°C until use.
Cell culture
The human ovarian cancer cell lines OV-CA-2774, SK-OV-3, and OV-CAR-3 were obtained from the American Type Culture Collection (ATCC; Bethesda, MD, USA). The cell lines were cultured in DMEM (Gibco BRL, Grand Island, NY, USA) containing 10% heat-inactivated fetal bovine serum (FBS; Gibco BRL), penicillin and streptomycin (Gibco BRL) in plastic tissue-culture dishes (Nunc, Rochester, NY, USA) at 37°C in a humidified atmosphere of 5% CO 2 .
Preparation of the O-Chol liposome
Dioleoyl phosphatidylethanolamine (DOPE) in chloroform was evaporated under a stream of N 2 gas, and further dried under vacuum. Cationic lipid (O-Chol) solubilized in water was added to the dried DOPE and vortexed (weight ratio of cationic lipid:DOPE = 1:1). After overnight incubation at 4°C for hydration, the mixture was sonicated using a bath-type sonicator.
Cytotoxicity assay in vitro
The MTT cytotoxicity assay of free liposomes was performed using a kit (Roche, Indianapolis, IN, USA). Each of the cell lines was seeded in 96-well plates (1-2 × 10 4 cells per well) and incubated for 1 day before experiments. Lipofectin (Gibco BRL), lipofectAMINE (Gibco BRL), DCChol (Sigma, St Louis, MO, USA), FuGENE 6 (Roche, Mannheim, Germany) and O-Chol were introduced into the cells and incubated for 48 h in the presence of serum. An MTT assay was performed according to the manufacturer's instructions. Cytotoxicity was determined by comparing the amount of MTT reduced by the cells treated with carriers with the amount reduced by control cells. 38 
Transfection of ovarian cancer cell line in vitro
For transfection, 10 5 cells per well were seeded in 24-well plates 1 day before transfection experiments, and grown in DMEM with 10% FBS. The cells were 60-70% confluent at the time of transfection. Complexes were prepared by mixing each reagent with 2 g plasmid DNA (pCNluciferase) per well in serum-free DMEM. Each complex solution was further incubated for 30 min at room temperature and added to the cells. Transfection was performed for 4 h. Medium was replaced with fresh complete medium and gene expression was assayed 48 h after transfection. Control transfections were performed using lipofectin, lipofectAMINE, DC-Chol, and FuGENE 6. The proportions of all transfection reagents were adjusted to the optimal conditions determined by preliminary experiments (data not shown): a 3:1 mass ratio of transfection reagent to plasmid DNA for the three ovarian cancer cell lines. In the case of the O-Chol liposome, the maximal level of expression was achieved at O-Chol:DNA = 1:1 mass ratio for the SK-OV-3 cell line, and a 3:1 ratio for the other cell lines. The same quantity of DOPE was added as a neutral helper lipid for maximal gene expression.
Assay for luciferase activity in vitro and in vivo and measurement of CAT in vivo
Luciferase activity was assayed using a kit purchased from Promega (Madison, WI, USA) and a TD-20/20 Lum-inometer (Turner Designs, Sunnyvale, CA, USA). After each well had been washed in phosphate-buffered saline (PBS), 100 l reporter lysis reagent was added to each well. After 30 min incubation at room temperature, each well was scraped. After centrifugation in a microcentrifuge for 5 min at 13 000 g at 4°C, a 20 l aliquot of supernatant was taken to assay luciferase activity by measuring the integration of the light produced during 20 s, starting 3 s after the addition of 100 l luciferase substrate to the cell lysate. The protein concentration of each supernatant was determined using a protein assay kit (Pierce, Rockford, IL, USA). Luciferase activity in each sample was normalized to the relative light unit (RLU) per milligram of protein.
Unless otherwise stated, mice were killed humanely 2 days after DNA transfer. The organs were removed and homogenized in complex solution of 1 ml luciferase lysis reagent and 1 ml CAT lysis reagent (Roche). The luciferase assay was performed with the same method used for the in vitro assay. After centrifugation, the amount of CAT in the supernatant was also quantified with a CAT ELISA kit (Roche) according to the manufacturer's instruction.
CAT expressing cancer cell line construction with retrovirus OV-CA-2774/CAT cells were generated as follows. The MIN-CAT-Neo vector (a kind gift from Sunyoung Kim, Seoul National University, Seoul, Korea) contains a fulllength E. coli CAT cDNA under the regulation of the retroviral long terminal repeat (LTR). The MIN-CAT-Neo vector was transfected into the TE-FLY-A/9 packaging cell line (a kind gift from Francois-Loic Cosset, Ecô le Normale Supérieure de Lyon, Lyon, France) with FuGENE 6. The culture medium containing retroviruses were collected and filtered through 0.45-m pore-sized filters (Millipore, Bedford, MA, USA). OV-CA-2774 cells (1 × 10 5 ) were seeded in 100-mm culture dishes supplemented with DMEM with 10% FBS 24 h before transduction. Retroviral supernatant mixed with 1.5 l 8 mg/ml polybrene (Sigma) was added to OV-CA-2774 cells. Fortyeight hours after transduction, stably transduced cells were selected by culture in the presence of 400 g/ml G418 (Gibco BRL) for 2 weeks. G418-resistant cells were tested for their ability to produce CAT. After verifying CAT gene expression, OV-CA-2774/CAT cells were maintained in DMEM with 10% FBS. in 300 l PBS were injected into the peritoneum of BALB/c-AnNCrj-nu/nu mice with a 30-gauge insulin syringe (Becton Dickinson, Franklin Lakes, NJ, USA), with subsequent repeated massage. A subset of mice was killed each week for 5 weeks. The organs were removed, homogenized, and either the luciferase activity or the amount of CAT quantified.
Development of peritoneal disseminated cancer
Intraperitoneal O-Chol/DNA complex injection in vivo
At 2 weeks after cancer inoculation, FuGENE 6, lipofectAMINE, or DC-Chol complexed with 100 g pCNluciferase in 300 l DMEM was injected into the peritoGene Therapy neum at the maximal expression ratio, ie a mass ratio of transfection reagent to plasmid DNA of 3:1. However, we used a mass ratio of O-Chol to DNA of 1:1 rather than 3:1, because at the higher lipid and DNA concentration used in vivo the O-Chol:DNA liposome complex aggregated easily and transfection efficiency decreased (data not shown). This drawback is a common feature of cationic liposomes. 39 Histochemical staining for ␤-galactosidase activity Two weeks after cancer inoculation, O-Chol complexed with 100 g ACP-nlsLacZ in 300 l DMEM was administered into the peritoneal cavity three times at 12-h intervals. For control animal, DMEM without O-Chol:DNA complex was injected into cancer-inoculated mice. At 24 h after the last injection, each organ in the injected mouse was removed and fixed with 4% paraformaldehyde (Sigma) in PBS for 1 h. This sample was incubated in a substrate solution (5 mM K 3 Fe[CN] 6 , 5 mM K 4 Fe[CN] 6 , 2 mM MgCl 2 , 10% sodium deoxycholate, NP-40, and 50 mg/ml X-gal in PBS) at 37°C overnight. To prepare stained cross-sections, each organ was embedded in OCT (Shandon, Pittsburgh, PA, USA), and 10-m sections were cut using a cryotome (Cryotome AS620, Shandon). Sections were collected on microscope slides (ProbeOn Plus microscope slides; Fisher Biotech, Pittsburgh, PA, USA), brought to room temperature, and stained with hematoxylin and eosin.
Statistical analyzis of results
Each set of conditions was tested in at least three different mice. Results are expressed as the mean ± s.e.m. Differences were tested by ANOVA for multiple-sample comparisons with Bonferroni's post hoc analyzis and by Tukey multiple comparison test using a generalized linear model (Figure 5c ). The level of significance was set at P Ͻ 0.05.
